Keywords: Takda, Pronova, TAK-085, Omacor, Japan regulatory filin, Cholesterol
Takeda and Pronova file for triglyceride lowererTAK-085 approval in Japan
Article | 29 September 2011
Norway-based lipid therapies specialist Pronova BioPharma says that its partner, Takeda Pharmaceutical (TYO: 4502), has submitted a New Drug Application to ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
